Evidence map›Paper›PMID 33095812›Full record

ArticlePloS one2020

Estimating the optimal interval between rounds of indoor residual spraying of insecticide using malaria incidence data from cohort studies.

Levicatus Mugenyi, Joaniter I Nankabirwa, Emmanuel Arinaitwe, John Rek, Niel Hens, Moses Kamya, Grant Dorsey

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Levicatus MugenyiCollege of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-9423-2472
Joaniter I NankabirwaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Emmanuel ArinaitweInfectious Diseases Research Collaboration, Kampala, Uganda.
John RekInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0003-4063-0763
Niel HensI-Biostat, Data Science Institute, Hasselt University, Hasselt, Belgium.
Moses KamyaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, California, United States of America.

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Training In Malaria Research in UgandaD43TW007375 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2005 to 2019
$2.9M
Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS D43 TW007375FIC NIH HHS D43 TW010526FIC NIH HHS K43 TW010365NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

backgroundIndoor residual spraying (IRS) reduces vector densities and malaria transmission, however, the most effective spraying intervals for IRS have not been well established. We estimated the optimal timing interval for IRS using a statistical approach.

methodsSix rounds of IRS were implemented in Tororo District, a historically high malaria transmission setting in Uganda, during the study period (3 rounds with bendiocarb active ingredient (Ficam®): December 2014 to December 2015, and 3 rounds with pirimiphos methyl active ingredient (Actellic 300®CS): June 2016 to July 2018). A generalized additive model was used to estimate the optimal timing interval for IRS based on the predicted malaria incidence. The model was fitted to clinical incidence data from a cohort of children aged 0.5-10 years from selected households observed throughout the study period.

results494 children, 67% aged less than 5 years at enrolment were analysed. Six-months period incidence of malaria decreased from 2.96 per person-years at the baseline to 1.74 following the first round of IRS and then to 0.02 after 6 rounds of IRS. The optimal time interval for IRS differed between bendiocarb and pirimiphos methyl and by IRS round. To retain an optimum impact, bendiocarb would require respraying 17 (95% CI: 14.2-21.0) weeks after application whereas pirimiphos methyl could remain impactful for 40 (95% CI: 37.0-42.8) weeks, although in the final year this estimates 36 (95% CI: 32.7-37.7) weeks. However, we could not estimate from the data the optimal time after the second and third rounds of bendiocarb and after the second round of pirimiphos methyl. Neither the amount of rainfall nor the EIR nor the distribution of nets were found to be statistically significant for determining the time period between spray rounds.

conclusionIn our setting, the effect of the two IRS products was distinct. Statistically, pirimiphos methyl provided a longer window of protection than bendiocarb, although impact varied between different spray rounds and years which was not explained by rainfall or EIR or distribution of nets in our statistical approach. Understanding the effectiveness of IRS and how long it lasts can help for planning campaigns, but one should consider the financial cost and insecticide resistance. Monitoring the timing of spray campaigns using clinical incidence could be repeated in future programs to help determine the average period of protectivity of these products.

Indexed as

InsecticidesOrganothiophosphorus CompoundsPhenylcarbamatesChildChild, PreschoolFamily CharacteristicsHumansIncidenceInfantMalariaMosquito ControlUgandabendiocarbInsecticidesOrganothiophosphorus CompoundsPhenylcarbamatespirimiphos methyl

Identifiers

PMID33095812
PMCPMC7584202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.